> DBV Technologies filed a biologics license application for Viaskin Peanut. The submission features data intended to address the FDA’s issues with the original filing. Statement
> A phase 2b/3 trial of TopiVert Pharma’s treatment for dry eye disease missed its primary endpoints. TopiVert plans to run another study of the drug. Release
> ObsEva secured a $75 million credit facility with Oxford Finance. The Swiss company will use the money to fund phase 3 trials. Statement
> MorphoSys signaled its intention to file for approval of tafasitamab in Europe. The plan is to complete the submission around the middle of next year. Release